Philips advances women’s health ultrasound with new single-transducer solution
Royal Philips introduced the eV14-2v transvaginal transducer, FDA 510(k) cleared and CE marked, expanding its obstetrics and gynecology ultrasound portfolio with a debut showcase at the 36th ISUOG World Congress. Philips says the single lightweight transducer delivers a 41.7% increase in penetration, a 10% increase in 2D resolution, a 15.8% wider field of view, and a 22% lighter design versus the 3D9-3v, reducing transducer switching during exams. Built on Philips' PureWave crystal technology, the eV14-2v works with Philips Collaboration Live for real-time remote consultation and supports delineation of fetal cardiac chambers as early as 13 weeks of gestation.
Key figures
- Revenue
- approximately EUR 18 billion (2025 sales, company boilerplate)
- Employees
- approximately 63,700
- Weight reduction
- 22%
- Comparison baseline
- 3D9-3v transducer
- Penetration increase
- 41.7%
- Resolution 2d increase
- 10%
- Field of view improvement
- 15.8%
- Fetal cardiac imaging weeks
- 13
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.